SILVER SPRING, Md. — The U.S. Food and Drug Administration (FDA) authorized the marketing for six nicotine pouch products ...
Altria relies on cigarettes as vapes face bans, flavors grow and on! competes with ZYN, with low multiple and 7.5% dividend ...
In late 2025, the FDA granted marketing authorization for six on! PLUS nicotine pouch products made by Altria Group’s Helix ...
We recently compiled a list of the 10 Best Long-Term Investments for Kids. Altria Group, Inc. stands tenth among the best ...
Altria ($MO) stock has risen about 9% over the past year, underperforming the nearly 17% rise in the S&P 500 Index (SPX).
Altria Group, Inc. presents compelling turnaround opportunity for 2026, driven by leadership transition & regulatory wins.
MO is moving beyond cigarettes as volumes fall, focusing on oral nicotine, e-vapor and heated tobacco to support growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback